Clinical Trial: Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Brief Summary: The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.
Detailed Summary:
Sponsor: Stanford University
Current Primary Outcome: To determine the hematologic response rate of imatinib in patients with HES.
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Stanford University
Dates:
Date Received: September 28, 2005
Date Started: June 2003
Date Completion:
Last Updated: April 11, 2011
Last Verified: April 2011